2019
DOI: 10.1148/radiol.2019182916
|View full text |Cite
|
Sign up to set email alerts
|

A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis

Abstract: Background: Although nephrogenic systemic fibrosis (NSF) affects the use of gadolinium-based contrast agents (GBCAs) in MRI, there continues to be limited knowledge because of the small number of patients with NSF. Purpose: To perform a systematic review of NSF. Materials and Methods: PubMed database was searched by using the term "Nephrogenic systemic fibrosis" from January 2000 to February 2019. Articles reporting details on individual patients with NSF diagnosis on the basis of both clinical presentations a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

3
71
0
2

Year Published

2019
2019
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 85 publications
(76 citation statements)
references
References 174 publications
3
71
0
2
Order By: Relevance
“…This new skin abnormality was termed nephrogenic fibrosing dermopathy. After recognition that other organs may be involved, including heart, lung, GI tract, CNS, kidneys, skeletal muscle, and diaphragm, the disease was renamed NSF (3,8). The lesions of NSF are usually symmetrical, develop on the limbs and trunk, and begin as a papule (skin colored or erythematous) which transitions to erythematous plaques with a peau d'orange appearance (9).…”
Section: J O U R N a L P R E -P R O O Fmentioning
confidence: 99%
See 1 more Smart Citation
“…This new skin abnormality was termed nephrogenic fibrosing dermopathy. After recognition that other organs may be involved, including heart, lung, GI tract, CNS, kidneys, skeletal muscle, and diaphragm, the disease was renamed NSF (3,8). The lesions of NSF are usually symmetrical, develop on the limbs and trunk, and begin as a papule (skin colored or erythematous) which transitions to erythematous plaques with a peau d'orange appearance (9).…”
Section: J O U R N a L P R E -P R O O Fmentioning
confidence: 99%
“…. A systematic review identifying 639 patients with biopsy-proven NSF demonstrated that 75.8% were exposed to gadodiamide and 12.1% to gadopentate dimeglumine, both linear GBCAs (3). The median interval between GBCA exposure and development of NSF was 42 days (interquartile range: 19-90 days).…”
Section: Joint Contractures Commonly Develop (mentioning
confidence: 99%
“…A 2019 systematic review of the literature found 639 patients with biopsy-confirmed NSF were administered almost exclusively nonionic linear agents at high doses (.0.1 mmol/kg). Of these patients, only seven confirmed cases of NSF occurred after 2008 (22). The authors concluded that regulatory actions and practice changes have been effective in reducing the incidence of NSF.…”
mentioning
confidence: 98%
“…Approximately 18% of cases were reported as a stable disease. Finally, Attari et al (10) estimated the rate of NSF cases per million exposures. Firstly, they assumed equal market share for high risk (Group I) and low risk (Group II) GBCA (see also Tables 1 and 2) and came to the rate of 1.52 per million exposures for high risk versus 0.008 per million exposures for low risk of GBCA.…”
mentioning
confidence: 99%
“…By assuming equal use of GBCA before versus after the implementation of warnings, regulatory restrictions and recommendations, the rate of NSF per million exposures decreased from 2.07 before 2008 to 0.028 after 2008. It is necessary to mention the fact, that Attari et al could not determine or estimate the number of GBCA exposures in high-risk subjects (10).…”
mentioning
confidence: 99%